Biel corporations marketing plan roll out has begun!
https://www.facebook.com/BioElectronics/
BIEL Corporation’s New Marketing Strategy
Yes — BioElectronics Corporation (BIEL) has launched a new marketing strategy combining targeted professional advertising, consumer social media campaigns, and a major licensing partnership with Haleon’s Voltaren brand to expand ActiPatch® reach. (?)
Key elements of the new strategy
1. Professional and consumer advertising push
According to Chairman Richard Staelin’s June 30, 2026 update, BIEL has initiated targeted advertising campaigns for medical professionals — including surgeons, pain specialists, rehabilitation providers, and chiropractors — to raise clinical awareness of its RecoveryRx technology NewMediaWire.
At the same time, the company has expanded consumer-focused social media advertising aimed at Generation X, designed to increase brand visibility among people seeking drug‑free chronic pain solutions NewMediaWire.
2. Strategic licensing with Haleon (Voltaren)
BIEL is integrating its ActiPatch® pulsed shortwave therapy (PSWT) technology into Haleon’s global Voltaren ecosystem InvestorsHub+1. This partnership involves:
Co‑branding Voltaren gel with ActiPatch for a “multi‑modal” pain relief product.
Distribution in major pharmacies (CVS, Walgreens, Boots) via Haleon’s retail network InvestorsHub.
Marketing leverage from Voltaren’s “#1 Doctor Recommended” status and multi‑million‑dollar brand campaigns InvestorsHub.
A 2027 Swiss pilot for Voltaren ActiPatch hybrids, with potential broader European/global rollout InvestorsHub.
3. Distribution and clinical outreach
BIEL is expanding outreach to physician‑owned ambulatory surgical centers and orthopedic practices, and is seeking a clinical trial partner for RecoveryRx to support future reimbursement under the federal NO PAIN Act NewMediaWire.
4. Operational focus
The company is shifting from in‑house marketing toward OEM and licensing models, relying on partners like Electrome for manufacturing and marketing scale Investors Hangout .
Why this matters
This marks a clear pivot from BIEL’s past niche device sales model to a brand‑driven, multi‑channel marketing approach that blends:
Professional credibility (clinical awareness campaigns)
Consumer reach (social media, retail partnerships)
Strategic alliances (Haleon/Voltaren) to bypass distribution and marketing barriers InvestorsHub+2.
In short: BIEL has indeed launched a new marketing strategy — one that is both brand‑building and partnership‑driven, with immediate professional and consumer campaigns and a long‑term rollout tied to Haleon’s Voltaren ecosystem.
Do your due diligence I for one will pick up some cheap shares while I can!
https://www.facebook.com/BioElectronics/
BIEL Corporation’s New Marketing Strategy
Yes — BioElectronics Corporation (BIEL) has launched a new marketing strategy combining targeted professional advertising, consumer social media campaigns, and a major licensing partnership with Haleon’s Voltaren brand to expand ActiPatch® reach. (?)
Key elements of the new strategy
1. Professional and consumer advertising push
According to Chairman Richard Staelin’s June 30, 2026 update, BIEL has initiated targeted advertising campaigns for medical professionals — including surgeons, pain specialists, rehabilitation providers, and chiropractors — to raise clinical awareness of its RecoveryRx technology NewMediaWire.
At the same time, the company has expanded consumer-focused social media advertising aimed at Generation X, designed to increase brand visibility among people seeking drug‑free chronic pain solutions NewMediaWire.
2. Strategic licensing with Haleon (Voltaren)
BIEL is integrating its ActiPatch® pulsed shortwave therapy (PSWT) technology into Haleon’s global Voltaren ecosystem InvestorsHub+1. This partnership involves:
Co‑branding Voltaren gel with ActiPatch for a “multi‑modal” pain relief product.
Distribution in major pharmacies (CVS, Walgreens, Boots) via Haleon’s retail network InvestorsHub.
Marketing leverage from Voltaren’s “#1 Doctor Recommended” status and multi‑million‑dollar brand campaigns InvestorsHub.
A 2027 Swiss pilot for Voltaren ActiPatch hybrids, with potential broader European/global rollout InvestorsHub.
3. Distribution and clinical outreach
BIEL is expanding outreach to physician‑owned ambulatory surgical centers and orthopedic practices, and is seeking a clinical trial partner for RecoveryRx to support future reimbursement under the federal NO PAIN Act NewMediaWire.
4. Operational focus
The company is shifting from in‑house marketing toward OEM and licensing models, relying on partners like Electrome for manufacturing and marketing scale Investors Hangout .
Why this matters
This marks a clear pivot from BIEL’s past niche device sales model to a brand‑driven, multi‑channel marketing approach that blends:
Professional credibility (clinical awareness campaigns)
Consumer reach (social media, retail partnerships)
Strategic alliances (Haleon/Voltaren) to bypass distribution and marketing barriers InvestorsHub+2.
In short: BIEL has indeed launched a new marketing strategy — one that is both brand‑building and partnership‑driven, with immediate professional and consumer campaigns and a long‑term rollout tied to Haleon’s Voltaren ecosystem.
Do your due diligence I for one will pick up some cheap shares while I can!
3
